Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer

Gene Therapy

Volumn 14, Issue 6, 2007, Pages 491-502

  Gao, J Q ^a   Kanagawa, N ^a   Motomura, Y ^a   Yanagawa, T ^a   Sugita, T ^a   Hatanaka, Y ^b   Tani, Y ^b   Mizuguchi, H ^c   Tsutsumi, Y ^c   Mayumi, T ^d   Okada, N ^a   Nakagawa, S ^a  

^a OSAKA UNIVERSITY   (Japan)

^b Dako Japan Co Ltd   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^d KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE CCL27; GAMMA INTERFERON; INTERLEUKIN 12; PERFORIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EXTRAMEDULLARY HEMATOPOIESIS; FIBROSARCOMA; GENE EXPRESSION; GENETIC TRANSDUCTION; IMMUNOHISTOCHEMISTRY; LIVER; LUNG; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CHEMOKINES, CC; FEMALE; FIBROSARCOMA; GENE THERAPY; GENETIC VECTORS; HEMATOPOIESIS, EXTRAMEDULLARY; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-12; LIVER; LUNG; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED STRAINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; SPLEEN; TRANSDUCTION, GENETIC;

MURINAE; MUS;

EID: 33847784176     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302892     Document Type: Article

References (46)

1. Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991; 88: 4143-4147.
2. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074-3081.
3. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): Cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992; 175: 779-788.
4. Brunda MJ. Interleukin-12. J Leukoc Biol 1994; 55: 280-288.
5. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA et al. Induction of interferon-γ production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-879.
6. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G. Mechanisms of IFN-γ induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992; 148: 92-98.
7. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547-549.
8. + T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993; 90: 10188-10192.
9. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994; 153: 1697-1706.
10. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-586.
11. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997; 90: 2541-2548.
12. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3: 409-417.
13. Okada Y, Okada N, Mizuguchi H, Takahashi K, Hayakawa T, Mayumi T et al. Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma. Biochim Biophys Acta 2004; 1670: 172-180.
14. Ogawa M, Umehara K, Yu WG, Uekusa Y, Nakajima C, Tsujimura T et al. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. Cancer Res 1999; 59: 1531-1538.
15. Iwasaki M, Yu WG, Uekusa Y, Nakajima C, Yang YF, Gao P et al. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models. Int Immunol 2000; 12: 701-709.
16. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX et al. Secondary lymphoid tissue chemokine mediates T celldependent antitumor responses in vivo. J Immunol 2000; 164: 4558-4563.
17. Fushimi T, Kojima A, Moore MA, Crystal RG. Macrophage inflammatory protein 3α transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 2000; 105: 1383-1393.
18. Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH et al. The CC chemokine CKβ-11/MIP-3β/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000; 164: 4025-4031.
19. Miyata T, Yamamoto S, Sakamoto K, Morishita R, Kaneda Y. Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1β mediated by a tumor-specific vector, HVJ cationic liposomes. Cancer Gene Ther 2001; 8: 852-860.
20. Guo J, Zhang M, Wang B, Yuan Z, Guo Z, Chen T et al. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 2003; 103: 212-220.
21. Gao J-Q, Tsuda Y, Katayama K, Nakayama T, Hatanaka Y, Tani Y et al. Antitumor effect by interleukin-11 receptor α-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. Cancer Res 2003; 63: 4420-4425.
22. Okada N, Gao J-Q, Sasaki A, Niwa M, Okada Y, Nakayama T et al. Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: Implications for chemokine-based cancer immunotherapy. Biochem Biophys Res Commun 2004; 317: 68-76.
23. Okada N, Sasaki A, Niwa M, Okada Y, Hatanaka Y, Tani Y et al. Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector. Cancer Gene Ther 2006; 13: 393-405.
24. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001; 78: 57-110.
25. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000; 12: 121-127.
26. Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1995; 1: 1179-1183.
27. Conry RM, Curiel DT, Strong TV, Moore SE, Allen KO, Barlow DL et al. Safety and immunogenicity of a DNAvaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002; 8: 2782-2787.
28. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
29. Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M et al. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/ lipoplex. Mol Ther 2002; 5: 609-616.
30. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1: 1297-1302.
31. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186: 1247-1256.
32. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6: 1011-1017.
33. Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med 1996; 2: 1090-1095.
34. Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 1999; 10: 697-709.
35. Lund RJ, Chen Z, Scheinin J, Lahesmaa R. Early target genes of IL-12 and STAT4 signaling in Th cells. J Immunol 2004; 172: 6775-6782.
36. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146.
37. Jackson JD, Yan Y, Brunda MJ, Kelsey LS, Talmadge JE. Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood 1995; 85: 2371-2376.
38. Tare NS, Bowen S, Warrier RR, Carvajal DM, Benjamin WR, Riley JH et al. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interferon Cytokine Res 1995; 15: 377-383.
39. Koizumi N, Mizuguchi H, Sakurai F, Yamaguchi T, Watanabe Y, Hayakawa T. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and αv integrin-binding ablation. J Virol 2003; 77: 13062-13072.
40. Eto Y, Gao J-Q, Sekiguchi F, Kurachi S, Katayama K, Maeda M et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 2005; 7: 604-612.
41. Okada Y, Okada N, Mizuguchi H, Hayakawa T, Nakagawa S, Mayumi T. Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma. Cancer Gene Ther 2005; 12: 608-616.
42. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Therapy 2001; 8: 730-735.
43. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998; 9: 2577-2583.
44. Mizuguchi H, Kay MA. A simple method for constructing E1-and E1/ E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999; 10: 2013-2017.
45. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR et al. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 1983; 131: 2445-2451.
46. Ledbetter JA, Herzenberg LA. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev s1979; 47: 63-90.